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 ABSTRACT 
 
Doxycycline (DOXY) is a tetracycline antibiotic with a potent antibacterial activity against a 
wide variety of bacteria. One potential strategy to enhance the penetration and the 
antibacterial activity of antibiotics is the use of nanotechnology. In this work, we report an 
innovative synthesis of a stable PEG-AuNPs loaded with DOXY. To the best of our 
knowledge, this is the first report on the combination of DOXY with gold nanoparticles as 
polymeric complex. The obtained nanoparticles were fully characterized by transmission 
electron microscopy (TEM), dynamic light scattering (DLS), zeta-potential, UV-Vis and 
Raman spectroscopy. The stability and sustained activity of the drug in nanoparticles was 
determined on a panel of Gram positive and Gram negative bacteria in comparison with the 
native form of the drug. This combined therapeutic agent restored the susceptibility of DOXY 
and showed an antibacterial activity against major human pathogens (Staphylococcus aureus, 
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter 
baumannii). Synergy of antibiotic with nanoparticles is quite promising, notably for antibiotic 
resistant strains. The antibacterial effect of combination of DOXY with gold nanoparticles 
was conserved despite the production of antibiotic resistance mechanisms in all the strains 
tested. Doxycycline-loaded nanoparticles could be used efficiently for antibacterial therapy, 
possibly against a large number of bacterial species. 
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1. INTRODUCTION 
Antibiotic resistance has been compared to as “the silent tsunami facing modern medicine”[1]. 
The broad use and the improper administration of antibiotics had make bacteria able to 
develop resistance against them. Many conventional antimicrobials became obsolete due to 
the emergence of multidrug-resistant pathogens 
[1]
. The chemical modification of antibiotic 
scaffolds to evade overcome bacterial resistance and to synthesize new antibiotics of high 
efficiency is time consuming and is often not economically feasible. Moreover, the antibiotic 
dosage often prescribed in some therapy is much higher leading to harmful side effects. For a 
successful antibiotic therapy, the antibiotic dose should be reduced and the stability should be 
increased to make the usage economical. One potential strategy to overcome this problem is 
the use of nanotechnology 
[2]
. Several studies have reported the antimicrobial activity of 
antibiotics conjugated with different nanoparticles 
[3]
 
[4]
 
[5]
 
[6]
 
[7]
.The combination of 
antibiotics to inorganic nanoparticles might enhance their antimicrobial effectiveness against 
multidrug resistant bacteria
[8]
. Moreover, nanoparticles were shown to take up by phagocytic 
cells that improves the delivery of antibiotics for the treatment of intracellular infections
[9]
. 
Gold and silver nanoparticles, as drug carriers, possess the potential to increase drug 
concentration at infected sites, combat its side effects and target the drug to the appropriate 
site of action
[10]
. As examples, Gu et al. have reported the enhanced antimicrobial activity of 
vancomycin coated gold nanoparticles on vancomycin resistant enterococci 
[11]
. Saha et al. 
demonstrated that the in vitro bactericidal activity of gold nanoparticles conjugated ampicillin, 
streptomycin and kanamycin were more efficient compared to their respective free forms
[12]
. 
Deng  et al have shown the synergic effect of amoxicillin with silver nanoparticles against 
Escherichia coli
[13]
. Rai et al. used cefaclor as both reducing and capping agent to produce 
spherical gold nanoparticles and showed a potent activity against both Gram-positive and 
Gram-negative bacteria
[3]
. Doxycycline (DOXY) (Scheme S1 Supporting Informations) has 
been recognized as a family of tetracycline antibiotics of very efficient antimicrobial 
activity
[14]
 
[15]
. The chemical structure of DOXY is very similar to doxorubicin (DOX)
[16]
.  
Both molecules contains a tetracyclic molecule, including planar and aromatic hydroxyl 
anthraquinone rings, which function as chromophore, responsible for therapeutic activity
[17]
 
[14]
. However, the formulation in use has shown dramatic side effects as their low 
bioavailability
[15]
, is responsible for delivery problems and consequently of systemic toxicity 
that limited their medical application
[18]
. Recently, J. Spadavecchia et al. have synthetized an 
original nanovector based on doxorubicin-gold-complex, by a chelation reaction in which, the 
drug was complex with tetrachloauric acid (HAuCl4) and polymer molecules before reduction 
to final nanovector (DOX IN AuNPs) 
[16]
 . The same authors have also studied the mechanism 
of hybrid nanoparticles using doxorubicin capped onto gold nanoparticles with biocompatible 
polymers as capping agent (DOX-ON AuNPs) in order to compare the different activity of 
both nanovectors 
[19]
 
[20]
, and their remarkable interest in therapeutic activity to in vitro model 
of Pancreatic Ductal Adeno Carcinoma (PDAC)
[19]
 
[16]
.   
In this paper, we combined gold nanoparticles (AuNPs) with DOXY by three chemical 
different methodologies (DOXY-AuNPs, DOXY ON-AuNPs, DOXY IN-AuNPs) and, 
evaluated the antimicrobial effect of these hybrids on several bacterial species in the presence 
of gold nanoparticles (AuNPs) synthetized. Therefore, the development of a simple and fast 
method to improve the activity of DOXY  and oxytetracycline has become increasingly 
attractive 
[13]
.  
The combination DOXY ON AuNPs exhibited the lower MICs (≤ 2 mg/L) in comparison 
with native DOXY in all species tested. Interestingly, the DOXY ON AuNPs was stable 
against the major resistance mechanisms to antibiotics acquired by human pathogen bacteria.  
 
 
 
2. RESULTS AND DISCUSSION 
Formation mechanism and physico-chemical characterization of Doxycycline 
Nanoparticles (DOXY-Au NPs, DOXY IN-Au NPs, DOXY ON-Au NPs,) 
In the last years many authors have produced antibiotic mediated synthesis of gold and silver 
nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings 
[3]
. 
Other authors have designed a nanocomposite based on DOXY -loaded polymeric 
nanoparticles in order to improve drug delivery and efficacy with considerable antimicrobial 
activity
[6]
 
[21]
 . In our case, the synthesis of DOXY-AuNPs (Scheme 1 A) was carried out at 
room temperature by reduction of gold ions (AuCl4
-
) using DOXY as reducing and capping 
agent on the growth process. A fast reduction in the time of gold ion, was observed when the 
reaction was performed at room temperature under basic conditions (NaOH). It is well 
established that amine and carbonyl groups can easily chelate and transfer electrons to gold 
ions (Au
3+
), leading to the formation of Au
0 
(nuclei)/ Au–amine complexes via simple amine-
carbonyl chemistry
[16]
 
[22]
 
[23]
. Pending the reduction of gold ions (AuCl4
-
) exploiting DOXY 
drives to a rise in the rate of reduction of the gold ions, which favors an enhanced nucleation 
rate with the formation of a gold grains
[24]
 
[25]
. Gold ions are consequently reduced on the 
surface of gold nuclei, therefore involving the achievement of spherical gold nanoparticles of 
smaller sizes, which are embedded and stabilized by DOXY (Scheme 1 A and scheme 2). In 
order to improve the stability and biological activity of the gold nanoparticles in object, we 
decided to apply some modification to original synthesis, through the methodology ON and 
IN extensively described by J.Spadavecchia et al.
[19]
 
[16]
 
[26]
 
[27]
 
Scheme 1 B showed a chemical procedure, named methodology IN, in which DOXY and 
PEG both participate actively to the stabilization of AuNPs via chelation between their 
chetone and amino groups with chloride auric ions. Chelation sites include the β-diketone 
system (positions 11 and 12) , the enol (positions 1 and 3) and carboxamide (position 2) 
groups of the A ring (see figure S1)
[28]
. 
The stacking process by electrostatic interaction between polymer (PEG) and DOXY-Au 
complex and final reduction in the presence of NaBH4 are responsible of final growth process 
and colloidal stabilization as previously described
[16]
 
[26]
 (scheme 1B). The third synthetic 
protocol, named methodology ON was depict in scheme 1C and performed in two main 
steps: 1) firstly, PEG-capped AuNPs were synthetized (PEG-AuNPs) and 2) further 
conjugated to DOXYL by carbodiimide chemistry between carboxylic group of PEG diacide 
onto AuNPs and amino group of DOXY as schematically showed. Based on our chemical 
design, the PEG-AuNPs appertain to the category of nanomedicines in which the drug 
payload is promptly conjugated to the nanoparticle surface via degradable covalent bond 
[19]
. 
The amide group binding the PEG chains to the DOXY molecules was designed so that it 
could be cleaved under the specific conditions in the cytoplasm releasing the drug in 
protonate form 
[5, 29]
.  At present it is recognized that the efficacy of antibacterial drugs is in 
many cases hampered by low antimicrobial concentration due to their poor bioavailability at 
the disease site. 
 
All nanoparticles of our chemical procedure were extensively characterized by UV-Vis 
absorption spectroscopy, TEM and Raman spectroscopy. When DOXY was mixed to the 
AuCl4
-
 solution, in the presence of NaOH, the formation of spherical gold nanoparticles 
(DOXY-AuNPs) of about 6.5 ± 0.7 nm was observed by TEM (Figure 1B-a).  
UV-Vis absorption spectroscopy analysis of DOXY-AuNPs products (Figure 1A; dark 
cyan) showed a clear band at 530 nm. The band positions are compared with spectroscopic 
band observed with individual DOXY molecules. This means that the DOXY could be 
present inside the solution as well as another compound. Moreover, the individual DOXY 
exhibits two pronounced UV-Vis absorption peaks at 346 nm and 274 nm. This 
spectroscopical finger print was associated to π-π* electronic transitions due to interactions 
between the DOXY ring and AuCl4
- 
ions
[30]
 making a clear demonstration of the complex 
formation. In agreement with previously studies
[16]
 
[26]
 
[27]
, we arrogate that  this band is due to 
electronic delocalization of aromatic ring and HOMO-LUMO transition and clear up  that 
DOXY was really involved into the nucleation process and builds a complex with Au.  
 
In the case of DOXY IN-AuNPs synthesis, PEG molecules improved the reduction process 
by interacting with the DOXY-AuCl4
-
 complex, stabilizing such complex and subsequently 
acting as surfactant in the nucleation and growth of the nanostructures. In particular, the 
formation of gold nanoparticles from AuCl4
-
 can be recapitulated in three steps (see scheme 
3): 
(1) Formation of DOXY-PEG diacid complex; (2) initial reduction of metal ions 
improved by DOXY and dicarboxylic acid-terminated PEG in aqueous solutions to form 
gold clusters; (3) adsorption of DOXY-PEG diacid complex on the surface of gold clusters 
and reduction of metal ions in that vicinity with consequently growth of gold particles and 
colloidal stabilization by molecules of PEG polymers. 
Interactions between AuCl4
-
 ions and mixture of DOXY-PEG diacid molecules (attractive 
ion-dipole interactions vs repulsive interactions due to hydrophobicity) are decisive in order to  
check the competition between AuCl4
-
 reduction, and the final particle size 
[31]
.  
  
DOXY IN-AuNPs absorption spectrum exhibits a small peak at 310 nm and a second one 
centered at 540 nm (Figure 1A red line). This latter peak is assigned to the localized surface 
plasmon of the nanoparticle with diameter of 23 nm embedded in PEG environment as 
expected 
[32]
. The AuNPs thus formed were characterized by TEM and have spherical shape 
(Figure 1B-b) with a diameter close to 23 ± 4.2 nm, confirmed by the hydrodynamic 
diameter measured by zetasizer (Table 1 in Supporting Information). Previously 
J.Spadavecchia et al. have reported the synthesis of similar nanostructures using dicarboxylic 
PEG 
[31, 33]
 
[34]
 obtaining PEG AuNPs as building block of nanovectors 
[19]
 
[16]
 
[26]
 
[27]
 . 
On the basis of previous studies, when DOXY was conjugate to PEG AuNPs by carbodiimide 
chemistry to form DOXY ON-AuNPs, we obtain a nanoconjugate in which DOXY was 
grafted on the surface of polymer-nanoparticle, taking on a different  chemical and  
conformation ( see scheme 4) .  We observe a red shift plasmon peak from 515 nm relative at 
PEG AuNPs (Figure 1 A –black line) to 525 nm (Figure 1 A –green line) with a different 
chemical and steric arrangement between PEG and DOXY onto the surface of AuNPs that 
influences the final size of the nanoparticles. 
TEM images show spherical gold nanoparticles with a mean diameter of about 13 nm ±1.2 
nm (Figure 1B-c). In addition, the bright red color of the obtained nanoparticles and the UV-
Vis spectra remain unaltered after storage for more than three months at room temperature 
validating the formation of stable particle suspension.  
The Raman spectra of free DOXY (control) , DOXY-AuNPs, DOXY IN-AuNPs  and DOXY 
ON-AuNPs in water exhibit many bands in the region 400-2000 cm
-1 
(Figure 2). The wide 
band observed around 1600 cm
-1
 on the raman spectra is assigned to the water. The bands for 
DOXY (Figure 2 blue line) were assigned in the following manner: frequencies at 1677 cm
-1
 
and 1537 cm
-1
 are related to the carbonyl and amino groups of the amide, respectively, in ring 
A; bands at 1613 cm
-1
 and 1581 cm
-1
 correspond to the carbonyl groups in rings A and C, 
respectively; the band at 1458 cm
-1
 is related to the C=C skeleton vibration. The oxygen 
atoms on C1 and C3 may be equivalent because there was only one frequency at 1615 cm
-1
.  
The triplet peak at 430-459-493 cm
-1
 is due to the vibrations δ (OH…O), ν (OH…O) of the 
DOXY molecule. For instance, a double peaks  at 1312 - 1270 cm
-1
  and 1175 cm
-1 
was 
assigned to C=O carbonyl stretching and C-O-C stretching in backbone of DOXY. When 
DOXY chelate to Au
3+
 to form DOXY-AuNPs ( Figure 2 - dark cyan)  in alkaline medium, 
we observed  an apparition of the peaks at 1386 cm
-1
 due to C-O plane deformation of amide 
group, 1542 cm
-1
 assigned to ν C-C stretching and a strong peak at  882 cm-1, due to C=O 
group of quinolone. For instance, a double peak at 1312-1270 cm
-1
 is lowered.  A triplet peak 
in the spectral region 430-493 cm
-1
 disappeared. These bands are due to variation of the steric 
conformation of the DOXY and become more prominent upon complexation, as described 
previously
[33a]
 
[34]
. These results were in part confirmed in DOXY IN-AuNPs, in which 
DOXY chelate to Au
3+
 in the presence of PEG diacid to form hybrid nanoparticles. The 
raman spectra clearly shows band changes of amide carbonyl and amino groups in ring A. 
Figure 2 red line showed an apparition of the peaks at 1423 cm
-1
,1370cm
-1
, 1284 cm
-1
,  due 
to C-O plane deformation of carboxylic acid,  and C=O carbonyl stretching of the PEG . 
However, the peaks for amide C=O of DOXY shifted from 1625-1657 cm
-1
 to 1633 cm
-1
 and 
those of –NH2 shifted from 1579 cm
-1
 to 1536 cm
-1
. These results suggest that the interaction 
of DOXY with PEG could take place through the amide C=O in ring A. A similar steric 
conformation of DOXY in hybrid nanoparticles (DOXY IN-AuNPs) compared to DOXY 
AuNPs was confirmed by a disappearance of triplet peak in the region 400-430 cm
-1
. These 
bands were assigned to DOXY aromatic rings vibrations and to those of C=O and hydroxyl 
groups in the DOXY molecule. It is   already previously described that most of the Raman 
bands of molecules can be significantly increased by their proximity to the surface AuNPs
[16]
. 
Thus, the enhancement of such bands is herein demontrated as a trial of the drug loading into 
AuNPs, as well as to their arrangement within the particles. When DOXY was grafted onto 
PEG-AuNPs, by carbodiimide chemistry to form DOXY ON AuNPs (Figure 2 green line), a 
strong spectroscopic variation was occurs. In particular we observed a SERS effect in the 
region 400-2000 cm
-1
. A double peak at 1462-1438 cm
-1
 is due to vibration N-H ; the increase 
of the peaks at 1364-1318-1275 cm
-1
 is due to a different C-O plane deformation of 
carboxylic acid,  and C=O carbonyl stretching of the PEG backbone. This result was 
confirmed by the shift of the peak from 1175 cm
-1
 to 1182 cm
-1
, due to C-O-C vibration. The 
steric and chemical conformation of DOXY onto the surface of PEG AuNPs was 
demonstrated by a strong SERS effect in the peak at 982 cm
-1
 due to C-O plane deformation 
in the ring of DOXY and the apparition of triplet peaks in the region 430-500 nm due to the 
vibrations δ(OH…O), ν(OH…O) of the DOXY molecule. Based on these findings, we 
conclude that DOXY assumes three different chemical conformations on the basis of 
chemical protocol to form hybrid nanoparticles. 
 
Stability of DOXY gold nanoparticles (DOXY-AuNPs, DOXY IN-AuNPs, DOXY ON-
AuNPs): 
The stability of DOXY gold nanoparticles in solution, pivotal a significant role in the 
clinical purposes
[35]
  and was monitored by  the Localized Surface Plasmon (LSP) band of the 
synthetized  AuNPs (scheme 1; Figure 1). Analysis was performed at pH 8 and electrolytic 
conditions over a reasonable period of time (3 months). The synthesized AuNPs did show an 
almost negligible change in the LSP band position over a period of three- months at the pH 8 
(Figure S1 in the Supporting Information). The decrease in intensity of plasmon peak, is due 
to agglomeration phenomena owing the oxidation process. Zeta potential measurements 
confirmed the spectroscopic results, showing that DOXY ON-AuNPs and DOXY-AuNPs 
were colloidally stable at physiological pH (z-potential = -25 ± 0.5 mV  and z-potential = 
-34 ± 0.8 mV  with a PdI equal to 0.3) (Table 1). We suggest that DOXY ON-AuNPs 
enhanced stability was associated with the presence of the PEG coating. The zeta 
potential of DOXY IN -AuNPs products in fact was found equal to -17.93 ± 0.7 mV, 
indicating a mild dispersion. The negative zeta potential suggested the presence of free 
negative charges in the sample, probably associated to free chloride ions (Cl
-
) and/or 
ionisable functions, such as the phenolic groups on the DOXY molecules present in the 
Au (III)-DOXY complexes.  
 
Drug loading and release of DOXY Nanoparticles (DOXY-Au NPs, DOXY IN-Au NPs, 
DOXY ON-Au NPs):  
Previously, A. Kumar et al. have studied the process of loading of DOXY onto chitosan 
nanoparticles to improve drug delivery and treatment efficacy
[6]
 .The effectiveness of a 
gradient loading system is highly dependent on the chemistry of the drug being loaded
[36]
. 
Gradient-loading systems in response to a pH gradient, have been developed for other 
antibacterial drugs, but differ from the method described in the current manuscript. We 
developed a novel loading methodology, resulting in pegylated nanoparticles with higher drug 
loading and longer retention times than passive aqueous capture
[37]
. Our loading efficiency is 
10–40 times more efficient than the previously published methods [36] [6] . 
Previous formulations of DOXY in DPPC/cholesterol liposomes used mannose or glucose 
solutions at a pH of 6.0 as non ionic hydrating solutions, and these formulations have 
encapsulation efficiencies of nearly 10-fold less than the sulfuric acid–loading technique[38].  
The percentage of released drug is dependent on the initial drug concentration, and 
equilibrium between the soluble drug and precipitate follows a zero-order process if the drug 
precipitates in the liposome
[39]
. Tu et al. used an ammonium sulfate gradient–loading system 
to describe the liposomal loading of the drug based on the amount of ammonium ion in the 
liposomes and the initial amount of drug added
[40]
.  
The successful loading ratio of DOXY onto PEG-AuNPs (DOXY ON-AuNPs) and 
complexed with AuCl4
-
 and PEG diacid (DOXY-AuNPs, DOXY IN-AuNPs) were evidenced 
by the characteristic absorption peaks at 273 nm and 345 nm from DOXY (Figure S2-A 
Supporting information). The standard absorption of DOXY was plotted in the inset of 
figure (Figure S2-B Supporting information) according to UV-Vis absorbance spectra of 
DOXY at various concentrations. The loading efficiencies were estimated to be 86% with 8.7 
µg present in 2.7×10
-8
 mol of NPs (data not shown) for DOXY ON-AuNPs, 65% for DOXY 
IN-AuNPs, and 54% for DOXY-AuNPs. DOXY releases were pH- and time-dependent 
(Figure 3 A-B). A sustained drug release was observed in the first 5 h for both drugs at pH 5 
and 8, which is highly favorable for drug delivery as the bacterial thrive in basic conditions. 
We presumed that the release of DOXY was checked by a ionic equilibrium between Au (III)-
PEG complexes trapped into AuNPs by the hydrophobic interactions between PEG chains and 
ionic drug. As previously described, the mechanism by which basic pH triggers drug release 
is probably associated to the presence of carboxylate groups in the chemical structure of PEG 
molecules. Such groups become dissociated in anionic form at basic pH. This improve the 
electrostatic interactions occurring between PEG and drugs that stabilize the DOXY ON 
AuNPs structure.  
 
We suppose that, the ionic strength and anionic form of DOXY onto PEG chains improve the 
water solubility of the drug molecules, taking advantage of the drug release from AuNPs. 
Indeed, a remarkable moiety of DOXY electrostatically binding onto dissociated complex is 
released, through PEG chain and diffusion phenomena 
[33a, 41]
. 
 
Extended spectrum of DOXY ON-AuNPs activity in bacteria 
It is well established that tetracyclines inhibit bacterial protein synthesis by preventing the 
association of aminoacyl tRNA with the bacterial ribosome
[42]
 
[43]
. Therefore, to interact with 
their targets these molecules need to traverse one or more membrane systems depending on 
whether the susceptible organism is gram positive or gram negative. The extensive structure-
activity studies have demonstrated that, the membrane-disrupting properties of the atypical 
tetracyclines are probably related to the relative planarity of the B, C, and D rings so that a 
lipophilic, non ionized molecule predominates. On interaction with the cell, the atypical 
tetracyclines are likely to be preferentially trapped in the hydrophobic environment of the 
cytoplasmic membrane, disrupting its function 
[43]
 .  
The presence of surfactant molecules onto the surface of nanoparticles, are usually 
undesirable , due to  their capacity  to block adsorption sites
[5]
. Heloiza F. O. Silva et al. have 
showed, that polyvinyl alchol (PVP), play a key role in linking with DOXY onto silver 
nanoparticles (AgNPs)
[5]
. They demonstrated, that less silver to be released, due to the layer 
size of the AgNPs and consequently, DOXY can release more easily followed  the disruption 
of ATP production and an increase in DNA mutation
[44]
. 
However, we have shown that PEG diacid played a paramount role in concentrating DOXY 
around the particle, which culminated in an increased bacteriostatic  activity. To evaluate the 
antibacterial activity of the synthetized nanoparticles, we selected a panel of bacteria 
frequently involved in clinical infections, including Gram positive and Gram negative bacteria 
(Tables 1, and 2). The MICs of compounds were compared with reference antibiotics 
(amoxicillin, ceftazidime, and imipenem). Whichever the bacteria tested the lowest MICs was 
measured in presence of DOXY ON-AuNPs (Tables 1, and 2). The MICs of DOXY ON-
AuNPs were 8 to 16 fold lower than that unmodified DOXY in Gram positive and negative, 
even in DOXY intrinsically resistant bacteria like P. aeruginosa. It is worth noting that the 
MIC values of DOXY ON-AuNPs were similar to that of reference antibiotics such as 
amoxicillin in S. aureus (ATCC

25923), and E. faecalis (JH2-2), and ceftazidime in 
P. aeruginosa (PAO1) and A. baumannii (CIP7010). Whereas the DOXY-AuNPs did not 
display antibacterial activity, the DOXY IN-AuNPs possessed a poor activity against Gram 
positive and negative bacteria. According to these results, we focused the susceptibility tests 
with DOXY ON-AuNPs, and DOXY IN-AuNPs. As antibiotic resistance is becoming a 
global critical issue particularly in ESKAPE pathogens including the species E. coli, S. aureus, 
K. pneumoniae, A. baumannii, P. aeruginosa, and E. aerogenes 
[45]
, we determined the MICs 
of DOXY ON-AuNPs, and DOXY IN-AuNPs in several ESKAPE pathogens, which were 
resistant to antibiotics by producing the most prevalent antibiotic resistance mechanisms in 
clinical isolates. While the S. aureus ATCC

700699 strain produces a PLP-2a responsible 
for resistance to methicillin (MRSA), the addition of ON-AuN, restored the susceptibility to 
DOXY (from >32 mg/L to 2 mg/L) as in susceptible strain ATCC

25923 (Table 1). 
Similarly, resistance to amoxicillin and vancomycin due to a modification of the PBP-5 and 
the acquisition of the transposon Tn1546 respectively, did not modify the susceptibility to 
DOXY ON-AuNPs (MIC = 2 mg/L) in strain BM4147
[46]
. All these data suggest that the MIC 
of DOXY ON-AuNPs is not affected by the most prevalent resistance mechanisms in Gram 
positive bacteria. 
 
Activity of DOXY IN-AuNPs and DOXY ON-AuNPs on P. aeruginosa  
P. aeruginosa is the most frequently pathogen in health care associated pneumonia infections 
in Europe 
[47]
. As few molecules are active on P. aeruginosa strains due to the production of 
several intrinsic resistance mechanisms, and its capacity to easily acquired mutations and 
foreign DNA, we assessed the impact of several resistance mechanisms to antibiotics on the 
activity of DOXY IN-AuNPs and DOXY ON-AuNPs 
[48]
.  
P. aeruginosa naturally produces an inducible cephalosporinase, AmpC, that may be 
overexpressed due to mutations in regulatory pathways genes (dacB, ampG)
[49]
. 
Overproduction of AmpC contributes to ceftazidime resistance, an antibiotic belonging to -
lactams family and usually used in first line of treatment of P. aeruginosa infections. As, the 
prevalence of AmpC mutants is high in clinical stains, we determined the MIC of DOXY IN-
AuN and DOXY ON-AuNPs in previously AmpC overproduction well-characterized clinical 
strains (Table 3) in comparison with that of ceftazidime. While the DOXY IN-AuNPs was 
more active (MIC from 4 to 8 mg/L) than DOXY (32 mg/L) like in susceptible strain PAO1, 
it remained less active than DOXY ON-AuNPs. In the five clinical strains (5134, 5168, 5250, 
5257, and 5268), the MICs of DOXY ON-AuNPs were identical (2 mg/L) and similar to the 
MIC of the susceptible strain PAO1 (2 mg/L) (Table 2, and 3) indicating that the activity of 
DOXY ON-AuNPs is not compromised in strains overproducing AmpC. However, 
P. aeruginosa may acquire additional -lactam resistance mechanisms, notably by the 
production of enzymes hydrolyzing these molecules (-lactamases) including Extended 
Spectrum -lactamases (ESBL), and carbapenemases. ESBL (Ambler class A -lactamases) 
and carbapenemases (Ambler class B, metallo--lactamases) have been largely reported in 
P. aeruginosa and have worldwide diffused 
[50]
.These enzymes contribute to the emergence of 
Multi-Drug Resistance strains (MDR), and eXtensively Drug Resistant strains (XDR)
[51]
. 
Whereas the strains were highly resistant to ceftazidime (MIC from 16 to>64 mg/L) and/or 
imipenem (MIC from 2 to >64 mg/L), the last therapeutic option in -lactams, the MICs of 
DOXY ON-AuNPs were not modified in strains producing ESBL (VEB-1a, SHV-2a, GES-1, 
and PER-1) or carbapenemases (VIM-2, IMP-13, IMP-15, and NDM-1). All these data show 
that DOXY ON-AuNPs is stable and is not affected (from 0.5 to 2 mg/L) by the major 
antibiotic resistance mechanisms identified in P. aeruginosa clinical strains. These promising 
results suggest that further studies with AuNPs combined with antibiotics are an interesting 
approach to challenge antibiotic resistance.  
Hypothetical mechanisms for antimicrobial activity of DOXY gold nanoparticles :  
There are many reports on the mechanism of antimicrobial activity of metallic nanoparticles. 
Unfortunately, the exact mechanism by which nanoparticle inhibits the growth of organism 
has not been well expounded. It was described by literature
[3]
 , that gold nanoparticles interact 
with the outer membrane of the bacteria through porin channels, and then accumulate on the 
membrane bilayer matrix,  thanks their interaction with lipopolysaccharide and protein 
[52]
 
damaging the membrane integrity. This behavior could explain the low antibacterial activity 
of gold nanoparticles. Although the mechanism behind the activity of DOXY hybrid 
nanoconjugate are not yet fully clarified, we suggest that the antibacterial activity of  DOXY 
ON-AuNPs is more better than , DOXY IN- AuNPs and DOXY-AuNPs, compared to DOXY 
free as control.  We believe that after conjugation of DOXY onto AuNPs, by EDC/NHS 
through PEG-COOH chains, DOXY was protonated and migrate through the PEG chains, 
assuming a favorite steric conformation to diffuse more freely in the cytoplasm as DOXY 
molecule charged positively, blocking the binding of aminoacyl-tRNA to the mRNA-
ribosome complex (scheme 4).   
The mechanism of enhanced antibacterial activity and advantages of DOXY reduced gold 
nanoparticles (DOXY-AuNPs) (scheme 5 A) can be explained as follows: DOXY reacts with 
the outer peptidogylcan layer of Gram-positive bacteria thereby increasing the membrane’s 
permeability, generation of reactive oxygen species (ROS) with oxidative deterioration to cell 
content. Subsequently, uptake of ions derived from nanoparticles, ATP production, and 
inhibition of DNA replication 
[52]
. Therefore, the combined action of DOXY and Au 
nanoparticles leads to enhanced antibacterial activity due to relase as DOXY-Au complex 
negatively charged. 
Contrarily, in the formulation DOXY IN-AuNPs, DOXY chelate Au(III) to form a complex 
before the staking process of PEG diacid chains; in this configuration, DOXY assume a 
different steric arrangement, in which hydriquinone and chetone groups in the ring B-C 
chelate Au ions before reduction with NaBH4 to form AuNPs. In this formulation, DOXY was 
released in the cytoplasm as DOXY-Au complex through migration in the PEG chains with 
evident variation in driven force and electrolytic condition (scheme 5B). 
 
 
Table 1. Susceptibilities of Gram positive bacteria. 
 
 MIC (mg/L) 
Species Staphylococcus aureus 
Enterococcus 
faecalis 
Enterococcus faecium 
Name of reference strains 
ATCC

 
25923 
ATCC

 
700699 
UCN41 BM4147 
ATCC

 
19434T 
DOXY 32 >32 >32 32 32 
DOXY NP-AuNPs 32 32 32 32 32 
DOXY IN-AuNPs 8 4 4 4 4 
DOXY ON-AuNPs 1 2 2 2 2 
Amoxicillin 1 8 1 8 1 
 
 
 
 
 
 
 
 
Table 2. Susceptibilities of Gram negative bacteria. 
 
 MIC (mg/L) 
Species E. coli 
Klebsiella 
pneumoniae 
Pseudomonas 
aeruginosa 
Acinetobacter 
baumannii 
Name of reference strains ATCC

 25922 ATCC 700603 PAO1 CIP7010 
DOXY 2 32 32 16 
DOXY NP-AuNPs >32 >32 >32 32 
DOXY IN-AuNPs 8 4 8 4 
DOXY ON-AuNPs 2 2 2 2 
Amoxicillin 0.12 >8 >256
a
 >256
a
 
Ceftazidime <0.12 0.12 2 2 
 
a 
Bacteria intrinsically resistant to amoxicillin.  
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Table 3. Susceptibilities of P. aeruginosa clinical strains producing various -lactamases. 
 MIC (mg/L)  
Name of clinical 
strain 
5134 5168 5250 5257 5268 5213 5231 5242 5176 5099 4925 5190 5225 5264 5269 
Resistance 
mechanism 
Strains overproducing the chromosomal 
cephalosporinase AmpC 
Strains producing a metallo--lactamase, carbapenemases Strains producing an ESBL
a
 
VIM-2 IMP-13 IMP-15 NDM-1 VEB-1a SHV-2a GES-1 PER-1 
DOXY 32 32 32 32 32 >32 32 32 32 32 32 32 32 >32 32 
DOXY IN-AuNPs 8 8 8 8 4 8 8 8 4 32 8 32 8 8 8 
DOXY ON-AuNPs 2 2 2 2 2 2 2 2 2 0.5 2 0.5 2 2 2 
Ceftazidime 32 4 64 4 >64 >64 >64 16 >64 64 >64 >64 16 >64 >64 
Imipenem 2 2 2 2 2 >64 >64 32 >64 16 >64 4 >32 2 >64 
 
 
a
 ESBL, Extended Spectrum--lactamase.  
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3. EXPERIMENTAL SECTION  
 Materials  
Tetrachloroauric acid (HAuCl4), sodium borohydride (NaBH4), N-hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (EDC), 
PEG-600 diacid, doxycycline hydrochloride (DOXY), bacterial culture media, was purchased from Sigma-Aldrich (St Louis, MO, USA). All solvents were reagent-
grade and used without any further purification. All bacteria were provided  by Laboratoire de Bactériologie, Centre National de Référence (CNR)  (France). 
Experiments were carried out at room temperature if not specified otherwise. 
Preparation of Nanoparticles 
Three strategies of synthesis were tested to conjugate DOXY to AuNPs: 
 Doxycycline reducing and formation of DOXY-AuNPs 
DOXY-AuNPs were synthesized by mixing 20 mL of HAuCl4 solution (8.63×10
-4
 M) with 4 mL of DOXY (1mg/mL) followed by the addition of 3 mL NaOH (1mM). 
After 15min of reaction, the as-prepared DOXY-AuNPs solution was centrifuged at 15.000 rpm for 30 min for three times to remove the excess of DOXY and then the 
supernatant was discarded, and the residue was redispersed in an equivalent amount of water. This was repeated twice.  
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Doxycycline loading into AuPEG and formation of DOXY IN-AuNPs 
Synthesis of DOXY IN-AuNPs colloids included three main steps: (Scheme 1C). 20 mL HAuCl4 solution (8.63×10
-4
 M) was mixed to DOXY (200 µL, 1 mg/mL in 
water) and aged for 10 min. After 10 min, 1 mL of dicarboxylic PEG was added. Finally, 300 µL of aqueous 0.01 M NaBH4 was added at once. After 15min of 
reaction, the as-prepared DOXY-AuNPs solution was centrifuged at 15.000 rpm for 30 min for three times to remove the excess of DOXY and PEG  and then 
the supernatant was discarded, and the residue was redispersed in an equivalent amount of water. This was repeated twice.  
 
 Doxycycline loading onto AuPEG and formation of DOXY ON-AuNPs 
Synthesis of pegylated- gold nanoparticles (PEG-AuNPs) 
Synthesis of AuPEG Colloids of COOH-terminated PEG-coated AuNPs (PEG-AuNPs) were prepared according to previously described procedure
[20]
 
[19]
 
[53]
 
[31]
. Briefly, 
20 mL of chloroauric acid (HAuCl4) aqueous solution (8.63×10
-4
 M) was added to 0.25 mL of dicarboxylic PEG and mixed by magnetic stirring for 10 minutes at room 
temperature. To this solution, 6 mL of aqueous 0.01 M NaBH4 was added at once. The color of the dispersion indeed instantly changed from yellow to red when sodium 
borohydride was added to a solution of gold precursor in the presence of PEG-diacid polymer, confirming the formation of AuPEG in the solution. The as-prepared PEG-
Au NP solution was purified by centrifugation to remove excess of non-conjugated dicarboxylic PEG. Centrifugation was carried out at 15,000 rpm for 30 minutes for 
three times in order to remove the excess of PEG and then the supernatant was discarded. The residue was redispersed in an equivalent amount of water. This was 
repeated twice. Conjugation of DOXY to PEG-AuNPs surface was carried out as from previous published work 
[19]
 using a carbodiimide-based conjugation of the 
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carboxylic-terminated polymer. Briefly, 50 μL of EDC/NHS (40/10 mg ratio) aqueous solution was added to 5 mL of PEG-AuNPs. After 2 hours, DOXY (50 µL, 
1mg/mL) was added and aged for 2 hours. The reaction mixture was then centrifuged three times and  
redispersed in water to remove any unbound DOXY. The encapsulation efficiency (percentage of DOXY bound to nanoparticles) was calculated as the difference between 
the initial drug content and the amount of free DOXY in the filtrate after separation of the nanoparticles by ultrafiltration (Ultrafree MC centrifugal filter units, 30,000 
NMWL; Merck Millipore, Darmstadt, Germany). The reaction efficiency was equal to 85%. 
 
Physico-chemical characterization  
All the measurements were performed in duplicate in order to validate the reproducibility of the synthetic procedure.  
 
 UV-Vis absorption spectroscopy: All experiments were performed as previously described 
[19]
 in water at AuNPs concentration equal to 10
-4 
M.  
Transmission Electron microscopy (TEM):  All microscopy analysis  were realized  as previously described
[19]
 
[16]
.  
 Raman Spectroscopy: The Raman experiments have been performed on an Xplora spectrometer (Horiba Scientifics-France). The Raman spectra have been recorded 
using an excitation wavelength of 785 nm (diode laser) at room temperature. For measurements in solution, a macro-objective with a focal length of 40 mm (NA = 
0.18) was used in backscattering configuration. The achieved spectral resolution is close to 2 cm
-1
. 
Dynamic light scattering (DLS): The size measurements were performed using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) equipped with a He-Ne 
laser (633 nm, fixed scattering angle of 173°) at room temperature. 
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Zeta potential measurements: All measurements were carried out as previously described 
[16]
. 
 
 
Stability of Doxy gold nanoparticles (DOXY-AuNPs, DOXY IN-AuNPs, DOXY ON-AuNPs) as a function of pH. 
For stability studies, all nanoparticles were dispersed in bacterial culture media (0.1 M; pH 8), and absorption spectra collected over 3 months (Figure S1 Supporting 
Informations).  
 DOXY loading efficiency: The amount of the antibiotic  incorporated into PEG-AuNPs was measured by UV-Vis absorption spectroscopy. Absorption at 350-275 nm 
was used to extrapolate DOXY concentrations based on a calibration curve (Figure S2 in the Supporting Information). Because the AuNPs spectrum could interfere 
with DOXY detection, the DOXY loading efficiency was calculated as follows (Equation 1): 
                             
     
  
      Equation 1 
Where C1 is the initial drug content and C2 is the amount of free doxorubicin in the filtrate
[16]
.  
 
Antimicrobial Assay 
 Bacterial strains 
Enterococcus faecalis UCN41, Enterococcus faecium BM4147 and ATCC19434T, Klebsiella pneumoniae ATCC700603, Escherichia coli ATCC25922, 
Acinetobacter baumannii CIP7010, and Pseudomonas aeuginosa PAO1 strains were used as reference strains 
[46, 54]
. P. aeruginosa clinical isolates were isolated from 
blood culture and tracheal aspirates at the teaching hospital of Besançon, France (CHRU Jean Minjoz). Well-characterized P. aeruginosa strains from the collection of 
the French National Reference Centre (NRC) for Antibiotic Resistance were also included in the study to evaluate the activity of the synthetized compounds derivative 
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from DOXY. The collection included 15 well-characterized resistant P. aeruginosa strains, of which 6 were carbapenems producers including 3 VIM-2, one IMP-13, 
one IMP-15, and one NDM-1, 4 Extended-Spectrum ß-Lactamases (ESBL) producers including (GES-1, PER-1, SHV-2a, and VEB-1a), and 5 AmpC overproducers.  
 
Susceptibility testing 
The minimum inhibitory concentrations (MICs) of the selected strains were determined by microdilution method in Mueller Hinton Broth (MHB, Becton Dickinson, Le 
Pont de Claix, France) containing adjusted concentrations of Ca
2+
 (from 20 to 25 mg/L) and Mg
2+
 (from 10 to 12.5 mg/L) according to Clinical and Laboratories 
Standards Institute recommendations 
[55]
. Briefly, from fresh bacterial cultures, microplates were inoculated with 10
5
 CFU/mL in MHB containing serial dilutions of 
molecules and incubated at 35°C for 18h. MICs of the molecules tested were compared to antibiotics usually used as reference according to the species. MICs were 
defined as the lowest concentration of antibiotic that completely inhibits visible growth after 24 h of incubation at 35°C. MICs of indicated antibiotics and molecules 
were determined in triplicate. 
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3. CONCLUSION 
 
In this study, we described a new approach to synthetize new antibacterial nanotherapeutics based on stable DOXY–gold nanoparticles. Chemical physics 
characterizations were extensively achieved and fully elucidated the formation mechanism of the nanostructure and the DOXY conformational changes associated with 
such processes. Infact, the amine group of DOXY acts as both a reducing and stabilizing agent and therefore the antibacterial activity of DOXY is preserved due to the 
presence of the free β lactam ring being available on the surface of the nanoparticles. The capping agents aren't needed on the surface of nanoparticles due to block 
potential adsorption surface sites. However, we have shown that PEG played a key role in the loading of DOXY around the particle, which culminated in an increased 
bactericidal activity towards major human pathogens (Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter 
baumannii). Thus, DOXY -loaded nanoparticles could be used efficiently for antibacterial therapy, against a variety number of bacterial species. Given these best-
quality results, this antibiotic system based on doxycicline constitutes a real promise as a therapeutic entity in disease treatment. Further studies are still envisaged, 
focused on no-cycline-cycline hybrid antibiotic nanoparticles in order to improve the selectivity and efficacy of the antibacterial system.  
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Scheme 1. Schematic representation of two possible mechanisms for the synthesis of DOXY-AuNPs, DOXY IN-AuNPs and DOXY ON-AuNPs. It should be noted 
that the scheme is not to scale. 
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Scheme 2: Schematic of proposed mechanism of AuCl4
-
 reduction and particle formation in the presence of DOXY as surfactant (Please note that drawings are not in 
scale and are not intended to be representative of the full samples composition).  
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Scheme 3: Schematic of proposed mechanism of AuCl4
-
 reduction and particle formation in the presence of DOXY and PEG-diacid as surfactants (Please note that 
drawings are not in scale and are not intended to be representative of the full samples composition). 
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Scheme 4: Representation of Doxycicline conjugation onto PEG-AuNPs by carbodiimide chemistry (Please note that drawings are not in scale and are not intended to 
be representative of the full samples composition). 
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Figure 1. A) UV-Vis spectra of the prepared AuNPs. B) TEM images and size distribution of the prepared DOXY-AuNPs (a,d), DOXY IN-AuNPs (b,e) and DOXY 
ON-AuNPs (c,f). 
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Figure 2. .Raman spectra of DOXY-AuNPs, DOXY IN-AuNPs and DOXY ON-AuNPs, DOXY powder and COOH-terminated PEG (PEG-COOH) are also reported 
for comparison. Experimental conditions: λexc = 785 nm; laser power 20 mW; 600 T of 120 s. 
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Figure 3: A) Drug release percentage (%) of DOXY ON AuNPs time in PBS (37 °C) at pH = 5.0 or at pH = 8.0. B) Schematic diagram of DOXY release under pH 
conditions. 
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Scheme 4: Scheme summarizing DOXY ON-AuNPs interaction with bacterial cells. (Please note that drawings are not in scale and are not intended to be representative 
of the full samples composition). 
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Scheme 5:  Scheme summarizing DOXY IN-AuNPs (panel A) and DOXY IN-AuNPs (panel B) interaction with bacterial cells. (Please note that drawings are not in 
scale and are not intended to be representative of the full samples composition). 
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Scheme S1: Chemical structure of doxycicline (DOXY).Rings are identified with letters from A to D; this nomenclature is used for Raman band assignments. 
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Table 1. Average hydrodynamic diameter and zeta potential of the prepared nanoparticles. 
Note: Data are reported as mode ± standard deviation. 
Particles Particle size (nm) PDI Zeta potential (mV) 
DOXY-AuNPs 11.59 ± 0.3 0.266 -34.70 ± 0.8 
DOXY IN-AuNPs 70.29 ±0.5 0.330 -17.93 ± 0.7 
DOXY ON-AuNPs 19.94 ± 0.6 0.238 -25.60 ± 0.5 
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Figure S1: Changes in the UV-Vis absorption spectra of DOXY gold nanoparticles when incubated in bacterial culture media  solution at pH 8, up to three months ( A: 
DOXY AuNPs; B: DOXY IN AuNPs; C: DOXY ON AuNPs) . 
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Figure S2: (a) UV-Vis absorption spectra of DOXY at increasing known concentrations. (b) A calibration curve (R
2
 = 0.9997) was extrapolated from such 
measurements. The amount of DOXY molecules contained into DOXY ON AuNPs, DOXY IN AuNPS and DOXY AuNPs  were  estimated based on this curve. 
 
